Introduction {#s1}
============

Both genetic and non-genetic factors are involved in the etiology of breast cancer. Known susceptibility variants include rare high-risk mutations, principally in *BRCA1* and *BRCA2*, more moderate susceptibility variants in genes such as *PALB2*, *CHEK2* and *ATM*, and more than 20 common genetic susceptibility variants conferring modest increased risks, principally identified through genome-wide association studies. Taken together, the known susceptibility variants have been estimated to explain about 20--25% of the observed familial breast cancer risk [@pgen.1003284-Mavaddat1]. There is still limited knowledge about how the relative risks of common susceptibility loci might be modified by the established reproductive and lifestyle risk factors (referred to as environmental risk factors) for breast cancer. Such knowledge could provide insights into common biological pathways for cancer development and further our understanding of breast cancer etiology for specific tumor subtypes. Previous reports of a possible interaction between variants in *FGFR2* and use of menopausal hormone therapy (MHT) were not confirmed [@pgen.1003284-Campa1]--[@pgen.1003284-Travis1]. All recent large studies found no statistically significant evidence of multiplicative gene-environment interaction between several common susceptibility loci and established risk factors for breast cancer after allowing for multiple comparisons [@pgen.1003284-Campa1], [@pgen.1003284-Travis1], [@pgen.1003284-Milne1]. The strongest previously reported findings were for an interaction between *LSP1*-rs3817198 and number of births (P-value = 0.002), between *CASP8*-rs104585 and alcohol consumption (P-value = 0.003), and between 5p12-rs10941679 and use of estrogen-only MHT (P-value = 0.007) [@pgen.1003284-Campa1], [@pgen.1003284-Travis1], [@pgen.1003284-Milne1]. This lack of statistical evidence of interaction beyond that expected by chance may be partly due to limited power to detect weak gene-environment interactions and not having considered specific subtypes of breast cancer. We used pooled data from 24 studies participating in the Breast Cancer Association Consortium (BCAC) to evaluate whether the relative risks of single nucleotide polymorphisms (SNPs) at 23 published loci vary according to levels of 10 established environmental risk factors [@pgen.1003284-Breast1]. Since there is etiologic heterogeneity by subtypes of breast cancer, we also carried out these assessments for breast cancer with positive and negative estrogen receptor (ER) status [@pgen.1003284-Yang1].

Results {#s2}
=======

Up to 34,793 invasive cases and 41,099 controls of self-reported European ancestry were included in these analyses ([Table 1](#pgen-1003284-t001){ref-type="table"}). Based on 18,532 cases and 25,341 controls from 16 population-based studies, we found the expected associations between the environmental risk factors and breast cancer risk ([Table 2](#pgen-1003284-t002){ref-type="table"}). As expected, significant effect heterogeneity by age (as a surrogate for menopausal status) was observed only for body mass index (BMI) (P-value = 0.007).
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###### List of participating studies and number of Caucasian subjects included in at least one GxE analysis.

![](pgen.1003284.t001){#pgen-1003284-t001-1}

  Study acronym                                                       Study Name                                                              Country                           Design category                     Cases/controls used for GxE   ER+ cases   ER−cases   Mean age (range) in cases   Mean age (range) in controls
  --------------- ------------------------------------------------------------------------------------------------------------------- ----------------------- ---------------------------------------------------- ----------------------------- ----------- ---------- --------------------------- ------------------------------
  ABCFS                                                  Australian Breast Cancer Family Study                                               Australia          Population-based[1](#nt101){ref-type="table-fn"}             1335/687                754        392            42.4 (23--69)                41.6 (20--68)
  CECILE                                                      CECILE Breast Cancer Study                                                      France                            Population-based                             938/1026                768        143            54.4 (25--74)                54.7 (25--74)
  CGPS                                                    Copenhagen General Population Study                                                 Denmark                           Population-based                             2388/6704              1800        357            62.0 (27--95)                55.7 (20--91)
  CTS                                                          California Teachers Study                                                        USA            Prospective cohort[1](#nt101){ref-type="table-fn"}            1252/1226             No Info    No Info          61.8 (32--83)                56.2 (26--77)
  ESTHER                                                      ESTHER Breast Cancer Study                                                      Germany                           Population-based                              433/511                293         85            60.3 (30--79)                62.3 (49--75)
  GENICA                                       Gene Environment Interaction and Breast Cancer in Germany                                      Germany                           Population-based                             1021/1015               755        216            58.2 (23--80)                58.2 (24--80)
  GESBC                                          Genetic Epidemiology Study of Breast Cancer by Age 50                                        Germany                           Population-based                              586/869                248        155            42.6 (20--50)                42.7 (24--52)
  KBCP                                                       Kuopio Breast Cancer Project                                                     Finland                           Population-based                              466/523                328         98            59.0 (23--92)                52.9 (17--77)
  MARIE                                               Mammary Carcinoma Risk Factor Investigation                                             Germany                           Population-based                             2583/5309              2008        533            62.5 (50--75)                61.9 (49--75)
  MCCS                                                   Melbourne Collaborative Cohort Study                                                Australia                         Prospective cohort                             703/766                424        141            61.4 (37--80)                57.2 (38--70)
  NC-BCFR                                          Northern California Breast Cancer Family Registry                                            USA                             Population-based                              268/154                203         35            56.9 (26--65)                56.9 (51--65)
  OFBCR                                                 Ontario Familial Breast Cancer Registry                                               Canada                            Population-based                             1135/328                634        260            53.8 (22--81)                57.4 (40--69)
  PBCS                                                      NCI Polish Breast Cancer Study                                                    Poland                            Population-based                             2009/2381              1204        622            55.7 (27--75)                55.7 (24--75)
  SASBAC                                               Singapore and Sweden Breast Cancer Study                                               Sweden                            Population-based                             1246/1515               711        160            63.0 (50--75)                63.4 (49--76)
  US3SS                                                          US Three State Study                                                           USA                             Population-based                             1444/1274             No Info    No Info          54.3 (29--69)                54.3 (27--75)
  USRT                                                     US Radiologic Technologists Study                                                    USA                             Population-based                             725/1053              No Info    No info          48.9 (22--82)                62.8 (42--94)
  BBCC                                                 Bavarian Breast Cancer Cases and Controls                                              Germany                Mixed[2](#nt102){ref-type="table-fn"}                   1432/1002               967        375            55.4 (22--96)                57.2 (18--100)
  BBCS                                                        British Breast Cancer Study                                                       UK                                   Mixed                                   1381/1297             No Info    No Info          53.9 (25--77)                51.4 (21--81)
  kConFab/AOCS     Kathleen Cuningham Foundation Consortium for research into Familial Breast Cancer/Australian Ovarian Cancer Study   Australia/New Zealand                         Mixed                                    499/962                156         65            45.0 (20--76)                58.3 (20--83)
  LMBC                                                  Leuven Multidisciplinary Breast Centre                                                Belgium                                Mixed                                   2890/1625              2290        416            56.6 (21--94)                44.1 (19--66)
  MCBCS                                                     Mayo Clinic Breast Cancer Study                                                     USA                                  Mixed                                   1803/2452              1475        292            56.8 (22--93)                56.6 (19--91)
  MSKCC                                              Memorial Sloan-Kettering Cancer Center Study                                               USA              Hospital-based[3](#nt103){ref-type="table-fn"}               425/455                256         66            47.1 (23--85)                47.0 (24--86)
  SBCS                                                       Sheffield Breast Cancer Study                                                      UK                                   Mixed                                   1111/1283               533        175            59.0 (28--92)                57.7 (45--80)
  SEARCH                                       Study of Epidemiology and Risk factors in Cancer Heredity                                        UK                                   Mixed                                   6720/6682              3758        977            53.3 (23--88)                58.4 (26--81)
  Total                                                                                                                                                                                                                     34793/41099             19565       5563                                

Studies that included all, or a random sample of all cases occurring in a geographically defined population during a specified period of time, and controls that were a random sample of the same source population as cases, recruited during the same period of time.

Studies not strictly population-based or hospital-based.

Cases diagnosed in a given hospital or hospitals during a specified period of time, and controls that were selected from the recruitment area as the cases during the same period of time.

10.1371/journal.pgen.1003284.t002

###### Main effects for the epidemiologic variables included in the analyses, derived from population-based studies only[1](#nt104){ref-type="table-fn"}.
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                                                                                                                 All          \<54 years       \> = 54 years                                                                                                             
  --------------------------------------------------------------------------------------------------------- ------------- ------------------- --------------- ----------- ------------------- -------------- ------------- ------------------- ------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
  Age at menarche (per 2 years)                                                                              17185/24136   0.93 (0.90--0.95)    7.8×10^−9^     6511/8987   0.90 (0.86--0.94)    1.0×10^−5^    10674/15149   0.93 (0.90--0.96)         3.3×10^−6^                                   ABCFS CECILE CGPS CTS ESTHER GENICA GESBC KBCP MARIE MCCS NC-BCFR OFBCR PBCS SASBAC US3SS USRTS
  Parous (yes/no)                                                                                            18265/25241   0.80 (0.76--0.85)    3.9×10^−15^    6807/9128   0.85 (0.78--0.93)     0.00051      11458/16113   0.77 (0.71--0.82)         3.7×10^−13^                                  ABCFS CECILE CGPS CTS ESTHER GENICA GESBC KBCP MARIE MCCS NC-BCFR OFBCR PBCS SASBAC US3SS USRTS
  Number of births (among parous)                                                                            15046/21771   0.90 (0.88--0.92)    7.9×10^−24^    5397/7635   0.92 (0.89--0.96)     0.00023      9649/14136    0.89 (0.87--0.91)         6.5×10^−21^                                  ABCFS CECILE CGPS CTS ESTHER GENICA GESBC KBCP MARIE MCCS NC-BCFR OFBCR PBCS SASBAC US3SS USRTS
  Age at first birth (per 5 years)                                                                           14671/21322   1.08 (1.06--1.11)    4.6×10^−11^    5327/7550   1.06 (1.02--1.11)      0.0031      9344/13772    1.10 (1.07--1.14)         3.4×10^−10^                                      ABCFS CECILE CGPS CTS GENICA GESBC KBCP MARIE MCCS NC-BCFR OFBCR PBCS SASBAC US3SS USRTS
  Ever breastfed (yes/no)                                                                                    11022/13182   0.90 (0.85--0.96)      0.0013       4174/4267   0.87 (0.79--0.97)      0.011        6848/8915    0.90 (0.83--0.97)           0.0073                                                ABCFS CECILE GENICA GESBC KBCP MARIE MCCS NC-BCFR OFBCR PBCS SASBAC US3SS
  Usual adult BMI (per 5 units)                                                                                  \-               \-                \-         5051/4905   0.92 (0.88--0.97)      0.0010       7557/9832    1.01 (0.97--1.05)            0.550            \<54: ABCFS CECILE GENICA GESBC KBCP MARIE NC-BCFR OFBCR PBCS SASBAC US3SS/\> = 54: ABCFS CECILE GENICA KBCP MARIE NC-BCFR OFBCR PBCS SASBAC US3SS
  Usual adult height (per 5 cm)                                                                              15861/18464   1.07 (1.05--1.09)    4.1×10^−13^    6096/5990   1.05 (1.02--1.08)      0.0017      9765/12474    1.08 (1.06--1.11)         3.4×10^−12^                                     ABCFS CECILE CTS ESTHER GENICA GESBC KBCP MARIE MCCS NC-BCFR OFBCR PBCS SASBAC US3SS USRTS
  Ever use of oral contraceptives(yes/no)                                                                    12812/15667   0.99 (0.93--1.05)       0.687       4762/4961   1.01 (0.91--1.13)      0.831       8050/10706    0.99 (0.92--1.06)            0.688                                                ABCFS CECILE ESTHER GENICA GESBC KBCP MARIE MCCS NC-BCFR PBCS SASBAC US3SS
  Duration of oral contraceptive use (per 5 years)                                                           12671/15478   1.02 (1.00--1.04)       0.021       4714/4914         1.05          (1.01--1.08)     0.0067         7957/10564       1.01 (0.99--1.04) 0.336                                       ABCFS CECILE ESTHER GENICA GESBC KBCP MARIE MCCS NC-BCFR PBCS SASBAC US3SS
  Current use of combined estrogen-progestagen therapy                                                           \-               \-                \-            \-              \-                \-         6425/9225    1.76(1.61--1.94)          6.9×10^−33^                                                               CECILE GENICA MARIE PBCS SASBAC US3SS
  Current use of estrogen-only therapy                                                                           \-               \-                \-            \-              \-                \-         6689/9457    1.19 (1.07--1.33)            0.001                                                                  CECILE GENICA MARIE PBCS SASBAC US3SS
  Duration of combined estrogen-progestagen therapy in current users (per 5 years)                               \-               \-                \-            \-              \-                \-         6337/9130    1.25 (1.20--1.30)         9.6×10^−27^                                                               CECILE GENICA MARIE PBCS SASBAC US3SS
  Duration of estrogen-only therapy in current users (per 5 years)                                               \-               \-                \-            \-              \-                \-         6596/9332    1.07 (1.03--1.12)         9.8×10^−4^                                                                CECILE GENICA MARIE PBCS SASBAC US3SS
  Lifetime intake of alcohol[2](#nt105){ref-type="table-fn"} (per 10 g/day)                                  6763/10273    1.03 (1.00--1.05)       0.035       2280/3162   1.05 (1.00--1.09)      0.0443       4483/7111    1.02 (0.99--1.05)            0.167                                                                       CECILE GESBC MARIE MCCS PBCS
  Smoking (ever/never)                                                                                       13725/16189   1.02 (0.98--1.07)       0.344       5292/5284   1.05 (0.97--1.14)      0.237       8433/10905    1.02 (0.96--1.08)            0.571                                                 ABCFS CECILE ESTHER GENICA GESBC KBCP MARIE MCCS OFBCR PBCS SASBAC US3SS
  Smoking amount(per 10 pack-years)                                                                          11890/14044   1.01 (0.99--1.03)       0.447       5030/5045   1.04 (1.00--1.08)      0.032        6860/8999    1.00 (0.98--1.03)            0.837                                                        ABCFS CECILE GENICA GESBC KBCP MARIE MCCS OFBCR PBCS US3SS
  Physical activity in year before reference date (square root of h/week)[3](#nt106){ref-type="table-fn"}     7211/1052    0.92 (0.87--0.97)       0.005       1759/1996   0.96 (0.89--1.02)      0.189        5452/8056    0.96 (0.93--1.00)            0.032                                                                     CECILE GENICA MARIE SASBAC US3SS

Model used for the assessment of epidemiologic main effects: logit(Pr(breast cancer\|risk factor)) = β~0~+β~1~\*study + β~2~\*reference_age + β~3~\*risk_factor.

Mean lifetime alcohol intake derived from duration and amount of alcohol intake in g/day at different age periods.

For physical activity, square root (hours/week) was used since this model gave the highest likelihood when modeling the marginal association using fractional polynomials (Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999;28(5):964-74.) and was further adjusted for menopausal status.

Except for *TGFB1*-rs1982073, all SNPs showed highly significant associations with breast cancer overall ([Table 3](#pgen-1003284-t003){ref-type="table"}). Eleven SNPs showed evidence of heterogeneity in the OR by ER status at p\<0.01. The per-allele OR overall and for subsets of women with information available for the risk factors considered were very similar to those previously published and provided no evidence of bias in OR estimates related to data availability (data not shown).

10.1371/journal.pgen.1003284.t003

###### Associations between selected SNPs and breast cancer risk in Caucasians, overall and by ER status (estimated per-allele odds ratios and 95% confidence intervals)[1](#nt107){ref-type="table-fn"}.
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  SNP                                           Locus      Gene      Allele   MAF[5](#nt111){ref-type="table-fn"}   N Cases/Controls   OR per allele (95%CI)     P trend     P het ER status[6](#nt112){ref-type="table-fn"}   ER+n (ca)     ER+OR (95%CI)       P trend     ER-n (ca)     ER-OR (95%CI)       P trend
  -------------------------------------------- ------- ------------ -------- ------------------------------------- ------------------ ----------------------- ------------- ------------------------------------------------- ----------- ------------------- ------------- ----------- ------------------- -------------
  rs11249433                                    1p11        \-        T/C                    0.401                    29502/31361        1.11 (1.09--1.14)     5.5×10^−19^                     3.6×10^−5^                        17670     1.13 (1.10--1.16)   7.8×10^−18^     5030      1.03 (0.98--1.07)      0.223
  rs17468277[2](#nt108){ref-type="table-fn"}    2q33     *CASP8*      C/T                    0.127                    29884/35245        0.94 (0.91--0.97)       0.00022                          0.019                          17589     0.97 (0.93--1.01)      0.090        4956      0.88 (0.83--0.94)     0.0025
  rs13387042                                    2q35       *-*        A/G                    0.484                    29732/34911        0.88 (0.86--0.90)     1.3×10^−26^                       0.00030                         17859     0.87 (0.85--0.90)   1.8×10^−23^     5085      0.94 (0.90--0.98)     0.0053
  rs4973768                                     3p24     *SLC4A7*     C/T                    0.466                    29300/33940        1.10 (1.08--1.13)     5.8×10^−17^                        0.005                          17643     1.11 (1.08--1.14)   5.7×10^−15^     5037      1.04 (1.00--1.09)      0.057
  rs10941679                                    5p12       *-*        A/G                    0.256                    29511/34613        1.12 (1.09--1.15)     1.3×10^−18^                     8.8×10^−5^                        17688     1.14 (1.11--1.18)   7.2×10^−18^     5110      1.03 (0.98--1.08)      0.288
  rs889312                                      5q11     *MAP3K1*     A/C                    0.278                    28387/29030        1.11 (1.08--1.14)     4.1×10^−15^                        0.038                          16446     1.12 (1.09--1.16)   1.7×10^−13^     4740      1.06 (1.01--1.11)      0.025
  rs12662670                                    6q25      *ESR1*      T/G                    0.076                    16518/15659        1.16 (1.09--1.23)     4.8×10^−7^                         0.073                          10810     1.12 (1.05--1.20)     0.00061       2705      1.22 (1.10--1.35)     0.00023
  rs2046210                                     6q25      *ESR1*      C/T                    0.341                    28196/29938        1.09 (1.06--1.12)     1.4×10^−11^                     6.4×10^−7^                        16713     1.06 (1.03--1.09)   6.42×10^−5^     4667      1.21 (1.16--1.27)   1.2×10^−15^
  rs13281615                                    8q24       *-*        A/G                    0.406                    27252/26610        1.13 (1.10--1.16)     7.5×10^−23^                        0.100                          16067     1.14 (1.11--1.17)   1.2×10^−18^     4635      1.08 (1.03--1.13)      0.016
  rs1011970                                     9p21    *CDKN2A/B*    G/T                    0.162                    23531/28641        1.09 (1.05--1.12)     2.2×10^−6^                         0.073                          14565     1.07 (1.03--1.11)     0.00010       4141      1.13 (1.06--1.21)   9.5×10^−5^
  rs865686                                      9q31       *-*        T/G                    0.381                    28077/31963        0.90 (0.88--0.92)     1.2×10^−17^                     6.1×10^−6^                        17037     0.88 (0.86--0.91)   4.9×10^−17^     4505      0.99 (0.94--1.03)      0.541
  rs10995190                                    10q21    *ZNF365*     G/A                    0.159                    22672/28655        0.88 (0.85--0.91)     1.6×10^−12^                        0.218                          13876     0.88 (0.84--0.91)   7.5×10^−10^     4028      0.91 (0.85--0.98)     0.0081
  rs704010                                      10q22    *ZMIZ1*      G/A                    0.383                    23456/28651        1.06 (1.03--1.09)     2.4×10^−5^                         0.150                          14528     1.05 (1.02--1.09)     0.00079       4132      1.02 (0.97--1.07)      0.468
  rs2981582                                     10q26    *FGFR2*      C/T                    0.383                    31807/33940        1.23 (1.20--1.26)     7.2×10^−73^                     2.0×10^−18^                       17973     1.28 (1.25--1.32)   2.1×10^−70^     5141      1.04 (1.00--1.09       0.053
  rs614367                                      11q13      *-*        C/T                    0.152                    21068/22008        1.21 (1.16--1.25)     4.8×10^−23^                     1.4×10^−9^                        12749     1.26 (1.21--1.32)   8.0×10^−26^     3777      1.02 (0.96--1.10)      0.509
  rs3817198                                     11p15     *LSP1*      T/C                    0.312                    28404/28438        1.09 (1.06--1.12)     5.6×10^−11^                        0.543                          16395     1.08 (1.04--1.11)   3.1×10^−6^      4743      1.07 (1.02--1.12)     0.0076
  rs10771399[3](#nt109){ref-type="table-fn"}    12p11    *PTHLH*      T/C                    0.117                    21182/18129        0.84 (0.80--0.88)     1.4×10^−12^                        0.590                          14392     0.86 (0.82--0.91)   3.3×10^−8^      3455      0.82 (0.75--0.90)   3.08×10^−5^
  rs1292011                                     12q24      *-*        T/C                    0.415                    17780/14298        0.94 (0.91--0.97)       0.00026                         0.0056                          12424     0.92 (0.89--0.96)   2.6×10^−5^      2935      1.00 (0.94--1.06)      0.887
  rs999737[4](#nt110){ref-type="table-fn"}      14q24   *RAD51L1*     T/A                    0.230                    29189/31066        0.93 (0.91--0.96)     1.3×10^−6^                         0.475                          17493     0.93 (0.90--0.96)   1.8×10^−5^      4985      0.95 (0.90--1.00)      0.062
  rs3803662                                     16q12     *TOX3*      C/T                    0.262                    27700/29192        1.24 (1.21--1.27)     8.3×10^−58^                       0.0036                          15802     1.26 (1.22--1.30)   1.0×10^−45^     4659      1.17 (1.12--1.23)   3.6×10^−10^
  rs6504950                                     17q23    *COX11*      G/A                    0.276                    29787/34101        0.93 (0.91--0.96)     2.2×10^−7^                        0.00057                         18028     0.92 (0.89--0.95)   1.3×10^−7^      5100      1.01 (0.96--1.06)      0.791
  rs1982073                                     19q13    *TGFB1*      T/C                    0.376                    17012/22985        1.04 (1.01--1.07)        0.020                           0.314                          9889      1.03 (1.00--1.07)      0.082        3032      1.07 (1.01--1.13)      0.018
  rs2823093                                     21q21    *NRIP1*      G/A                    0.267                    18655/16443        0.95 (0.92--0.98)       0.0038                           0.121                          12927     0.94 (0.91--0.98)     0.0031        2972      1.00 (0.93--1.06)      0.898

model used for the assessment of SNP main effects: logit(Pr(breast cancer\|SNP)) = β~0~+β~1~\*study + β~2~\*SNP.

or the highly correlated SNP rs1045485 (*r^2^* = 1 in HapMap CEU).

or the highly correlated SNP rs1975930 (*r^2^* = 1 in HapMap CEU).

or the highly correlated SNP rs10483813 (*r^2^* = 1 in HapMap CEU).

MAF: minor allele frequency among controls.

P-value for heterogeneity by ER-status: from case-case analysis.

The strongest evidence was found for modification of the association with *LSP1-*rs3817198 by number of births in parous women (P~interaction~ per birth increase in parous women = 2.4×10^−6^) ([Table 4](#pgen-1003284-t004){ref-type="table"}; [Figure 1](#pgen-1003284-g001){ref-type="fig"} showing individual study results). Since this interaction was previously assessed in BCAC, we reassessed the interaction in 6266 cases and 3899 controls not included in the previous report [@pgen.1003284-Milne1]. The SNP association still varied significantly with number of births in parous women (P~interaction~ = 1.6×10^−3^), thus independently replicating the previous finding. The results were consistent across studies (P~heterogeneity~ = 0.37) ([Figure 1B](#pgen-1003284-g001){ref-type="fig"}). In the overall dataset, the per-allele OR (95% confidence interval) for rs3817198 ranged from 1.03 (0.96--1.10) in parous women with one birth to 1.26 (1.16--1.37) in women with four or more births ([Figure 2](#pgen-1003284-g002){ref-type="fig"}) and in comparison was 1.08 (1.01--1.16) in nulliparous women ([Table S4](#pgen.1003284.s004){ref-type="supplementary-material"}).

![Odds ratios of gene-environment interaction for risk of breast cancer with p-value\<10^−3^ by study.\
(A) *LSP1*-rs3817198 x Number of full-term births (among parous), (B) *LSP1*-rs3817198 x Number of full-term births (among parous), restricted to subjects not included in previous BCAC report, (C) 1p11-rs11249433 x Parous (yes/no), (D) *CASP8*-rs17468277 x mean lifetime intake of alcohol (\<20 g/day versus \> = 20 g/day).](pgen.1003284.g001){#pgen-1003284-g001}

![Per-allele SNP odds ratios and 95% confidence intervals stratified by environmental risk factors of breast cancer, and combined SNP main effect.\
(A) *LSP1*-rs3817198 x Number of full-term births (among parous), (B) 1p11-rs11249433 x Parous (yes/no), (C) *CASP8*-rs17468277 x mean lifetime intake of alcohol (\<20 g/day versus \> = 20 g/day).](pgen.1003284.g002){#pgen-1003284-g002}

10.1371/journal.pgen.1003284.t004

###### Per-allele odds ratios and 95% confidence intervals for SNPs by environmental risk factors of breast cancer showing interaction P-value\<10^−3^, overall and by estrogen receptor status.

![](pgen.1003284.t004){#pgen-1003284-t004-4}

                                                                                                                                                 All       Estrogen receptor-positive   Estrogen receptor-negative                                                                             
  ----------------------------------------------------- ------------------------------------------------------------------------- --------- ------------- ---------------------------- ---------------------------- ------ ------- ------------------- ------------ ------ ------------------- ------------
  rs3817198 (*LSP1*)                                                      Number of births (among parous women)                       1       4957/4464        1.03 (0.96--1.10)                                            2970    1.02 (0.95--1.10)                936    0.98 (0.87--1.10)  
                                                                                                                                      2      10549/10234       1.07 (1.02--1.11)                                            6044    1.05 (1.00--1.11)                1800   1.05 (0.97--1.14)  
                                                                                                                                      3       4970/4821        1.16 (1.09--1.23)                                            2871    1.15 (1.07--1.24)                780    1.13 (1.00--1.27)  
                                                                                                                                   \> = 4     2588/2632        1.26 (1.16--1.37)                2.4×10^−6^           0.33   1453    1.26 (1.13--1.40)   5.6×10^−5^   416    1.26 (1.06--1.49)   5.7×10^−3^
  rs11249433(1p11)                                                                       Parous                                      No       4243/3796        0.98 (0.92--1.05)                                            2543    0.97 (0.90--1.04)                720    0.96 (0.85--1.08)  
                                                                                                                                     Yes     24226/25432       1.14 (1.11--1.17)                5.3×10^−5^           0.15   14443   1.16 (1.13--1.20)   1.6×10^−5^   4203   1.04 (0.99--1.10)      0.19
  rs17468277[3](#nt115){ref-type="table-fn"}(*CASP8*)    Mean lifetime intake of alcohol[4](#nt116){ref-type="table-fn"} (g/day)    \<20      5630/8547        0.91 (0.85--0.98)                                            3965    0.94 (0.87--1.02)                1315   0.88 (0.78--1.00)  
                                                                                                                                   \> = 20     451/758         1.45 (1.14--1.85)                3.1×10^−4^           0.30    345    1.48 (1.14--1.91)     0.001       83    1.22 (0.77--1.94)      0.18

P-value for GxE interaction from logistic regression analysis stratified by study and adjusted for reference age. The interaction term was the product between the continuous SNP variable (number of risk alleles) and the risk factor variable (continuous for number of births and dichotomized for ever being parous and for mean alcohol intake): logit(Pr(breast cancer\|risk factor, study, SNP)) = β~0~+β~1~\* reference_age + β~2~\*SNP + β~3~\*risk_factor + β~4~\*SNP\* risk_factor.

P-value for study heterogeneity from fixed effects meta-analysis of case-control analyses per study.

or the highly correlated SNP rs1045485 (*r^2^* = 1 in HapMap CEU).

mean lifetime alcohol intake derived from duration and amount of alcohol intake in g/day at different age periods.

The polymorphism 1p11.2-rs11249433 was associated with breast cancer in parous (1.14, 1.11--1.17) but not nulliparous women (0.98, 0.92--1.05) (P~interaction~ = 5.3×10^−5^). The interaction was non-significantly stronger for risk of ER-positive than ER-negative tumours (P~heterogeneity~ = 0.13, [Table S5](#pgen.1003284.s005){ref-type="supplementary-material"}, [Table S6](#pgen.1003284.s006){ref-type="supplementary-material"}), corresponding to this SNP being more strongly associated with ER-positive disease ([Table 3](#pgen-1003284-t003){ref-type="table"}). When restricted to ER-positive breast cancer, the per-allele OR for rs11249433 was 1.16 (1.13--1.20) in parous women and 0.97 (0.90--1.04) in nulliparous women (P~interaction~ = 1.6×10^−5^) ([Table 4](#pgen-1003284-t004){ref-type="table"}). There was no significant heterogeneity in the interaction ORs by study ([Figure 1C](#pgen-1003284-g001){ref-type="fig"}).

For the previously reported potential interaction between *CASP8*-rs1045485 (in complete LD with rs17468277) and alcohol consumption (\<1 versus ≥1 drink/day) [@pgen.1003284-Travis1], we found moderate evidence when assessing effect modification by alcohol intake per 10 g/day increase (P~interaction~ per 10 g/day = 3.0×10^−3^) ([Table S4](#pgen.1003284.s004){ref-type="supplementary-material"}). However, when alcohol intake was dichotomized at 20 g/day (approximately 2 drinks/day), the estimated per-allele OR for *CASP8*-rs17468277 was 0.91 (0.84--0.98) in those who drank \<20 g/day and 1.45 (1.14--1.85) in those who drank ≥20 g/day (P~interaction~ = 3.1×10^−4^) ([Table 4](#pgen-1003284-t004){ref-type="table"}, [Figure 1D](#pgen-1003284-g001){ref-type="fig"}).

We observed weaker evidence of differences in the associations with breast cancer for three further SNPs according to use of MHT and for one SNP according to age at first birth. These included rs13387042 and current use of combined estrogen/progestagen MHT (yes/no) (P~interaction~ = 2.4×10^−3^), rs2823093 and current use of estrogen only MHT (yes/no) (P~interaction~ = 6.6×10^−3^), rs999737 and duration of estrogen only MHT among current users (P~interaction~ = 4.0×10^−3^), and rs614367 and age at first birth among parous women (P~interaction~ = 9.1×10^−3^) ([Table S4](#pgen.1003284.s004){ref-type="supplementary-material"}).

The observed SNP-environmental interaction ORs were not altered substantially (less than 8% change in the interaction ORs) when adjusting for additional covariates. These additional covariates included (when not the potentially effect-modifying variable of interest) ever parous (yes/no), number of births, BMI, age surrogate for postmenopausal status (≥54 years), interaction of BMI and postmenopausal status (≥54 years), current use of MHT, past use of MHT, duration of oral contraceptives (OC) use, lifetime alcohol intake, smoking (pack-years) ([Table S7](#pgen.1003284.s007){ref-type="supplementary-material"}). Subjects with missing covariable information were excluded from these analyses, leading to considerably reduced sample sizes. Restricting the analyses to only 16 population-based studies did not change the results substantially (i.e., less than 3%) ([Table S8](#pgen.1003284.s008){ref-type="supplementary-material"}).

The false-positive report probability (FPRP) was below 0.2 at a prior probability greater than 0.001 for the replicated effect modification of *LSP1-*rs3817198 by number of births and 1p11.2-rs11249433 and being ever parous. For the effect modification of *CASP8*-rs17468277 by alcohol intake ≥20 g/day, the FPRP was below 0.2 at a prior probability greater than 0.01. For the four potential interactions reported above, the FPRP was only below 0.2 at a prior probability greater than 0.05. ([Table S9](#pgen.1003284.s009){ref-type="supplementary-material"}).

Discussion {#s3}
==========

We carried out a comprehensive evaluation of potential gene-environment interactions between 23 established common susceptibility variants for breast cancer and 10 established environmental risk factors, using 18 variables. Compared to the previous analysis, the present dataset from BCAC included 5 new population-based studies as well as additional study participants from some studies [@pgen.1003284-Milne1]. We examined additional environmental risk factors (14 variables), and 11 additional recently identified common susceptibility loci.

In our previous report, the strongest evidence of effect modification (P-value = 0.002) was observed for *LSP1-*rs3817198 by number of births [@pgen.1003284-Milne1]. The highly consistent and significant finding based on the present analysis of only additional cases and controls provided clear independent replication. We also show that the interaction holds for both ER-positive and ER-negative disease. This lack of heterogeneity is biologically plausible since neither the SNP nor number of births show heterogeneity by ER status in association with breast cancer risk [@pgen.1003284-Yang1], [@pgen.1003284-Broeks1]. Only ever parous versus nulliparous but not the number of births in parous women was assessed for gene-environment interaction in two previous studies [@pgen.1003284-Campa1], [@pgen.1003284-Travis1]. Consistent with our data indicating no differential effects by ever parous compared to never parous, they did not find evidence of interaction between *LSP1*-rs3817198 and ever being parous. The rs3817198 SNP is located on the short arm of chromosome 11 and lies within *LSP1*, encoding lymphocyte-specific protein 1, an intracellular F-actin binding protein, although the gene underlying the association has not been definitively identified. The SNP lies close to the H19/IGF2 imprinted region, and the association of breast cancer with rs3817198 has been reported to be restricted to the paternally inherited allele [@pgen.1003284-Kong1]. The effect heterogeneity of *LSP1*-rs3817198 by number of births appears to be partly due to a significant negative correlation between number of rs3817198 C alleles and number of births in parous women (P-value = 0.002), which was found both in the data of our previous report as well as the additional data for the present analysis. Although not statistically significant, the mean number of children was also reported to be lower in women carrying the CC genotype in the Million Women Study [@pgen.1003284-Travis1]. Also of interest is that *LSP1*-rs3817198 has been associated with mammographic density, consistent with the direction of the breast cancer association [@pgen.1003284-Vachon1]. Mammographic density has also been found to be reduced after a full-term pregnancy, particularly with greater number of births [@pgen.1003284-Butler1], [@pgen.1003284-Loehberg1].

We also replicated the strongest finding reported in the Million Women Study based on 7,610 cases and 10,196 controls [@pgen.1003284-Travis1]. In that study, the per-allele OR of *CASP8*-rs1045485 (or rs17468277 in our dataset) was 0.99 (0.92--1.07) in those who reported \<1 drink/day and 1.23 (1.09--1.38) in those who reported ≥1 drink/day (P-value = 0.003). Our observation of an increased per-allele OR of 1.45 (1.14--1.85) for those who reported high alcohol intake ≥20 g/day and 0.91 (0.84--0.98) for those who consume less provides independent replication of this SNP-environmental interaction. Although one drink corresponds to an intake of approximately 10 g alcohol, the Million Women study reported the strongest risk increase in breast cancer for women consuming at least 15 drinks per week (RR 1.29 (1.23--1.35)) [@pgen.1003284-Allen1], corresponding to approximately to 2 drinks per day (20 g alcohol). There is no known functional effect of *CASP8*-rs1045485, however, it is associated with a risk haplotype in *CASP8*, which is more strongly associated with breast cancer risk [@pgen.1003284-Camp1], [@pgen.1003284-Cox1]. Caspase 8 is an important initiator of apoptosis and is activated in response to DNA damage that can be caused by alcohol consumption through ethanol-related oxidative stress [@pgen.1003284-Dumitrescu1].

Ever being parous, but not number of births, was found to modify the effect of a different SNP, 1p11.2-rs11249433, in particular for ER-positive breast cancer. This SNP shows significantly stronger association with risk of ER-positive tumors than of ER-negative tumors [@pgen.1003284-Figueroa1]. In nulliparous women, rs11249433 was not associated with risk of ER-positive disease, whereas in parous women, the per-allele OR of 1.14 was slightly greater than the overall OR of 1.12. The Breast and Prostate Cancer Cohort Consortium evaluated interactions between 13 of the 23 genetic loci and 9 risk factors, including 1p11.2-rs11249433 and ever parous. They found no evidence for this interaction (P-value = 0.79), with per-allele OR of 1.09 (1.04--1.14) in parous and 1.11 (0.99--1.24) in nulliparous women [@pgen.1003284-Campa1]. These ORs are not in the same relative direction as our finding with respect to ever being parous. This may be in part due to misclassification of parity if information on parity for participants of the cohort studies was only available at time of recruitment and therefore incomplete with reference to the diagnosis of breast cancer. Their analysis was based on 8,576 cases and 11,892 controls, which had considerably lower statistical power than the present study. The SNP rs11249433 is located on the short arm of chromosome 1 close to the centromere, which makes it hard to map. The nearest known genes are *FCGR1B* (low-affinity Fc gamma receptor family) and *NOTCH2* (coding a transmembrane receptor protein). Recently, a study reported a positive association of *NOTCH2* mRNA expression with the breast cancer risk allele of rs11249433 [@pgen.1003284-Fu1]. This association was strongest with the subgroup of ER-positive breast tumors without TP53 mutation, providing some evidence that the increased risk of ER-positive breast cancer might be due to differences in *NOTCH2* expression [@pgen.1003284-Fu1].

The evidence for the other four potential interactions mentioned in the results was considerably weaker and confirmation of these findings in further studies is therefore required. Three of these involved effect modification by use of MHT. The effect modification of *RAD51L1*-rs999737 by duration of estrogen only MHT in current users is particularly interesting because this polymorphism has been associated with mammographic density in the same direction as the breast cancer association [@pgen.1003284-Vachon1]. Mammographic density has also been found to be increased in postmenopausal women among users of MHT [@pgen.1003284-Boyd1].

*RAD51L1* is a member of the Rad51-like proteins that play a crucial role in homologous recombinational repair [@pgen.1003284-Lio1]. Rare deleterious mutations in other genes of this pathway, including *BRCA1* and *BRCA2*, confer a high risk of breast cancer [@pgen.1003284-Mavaddat1], [@pgen.1003284-Meindl1]. Menopausal hormone therapy has been suggested to alter breast cancer risk in *BRCA1* mutation carriers although the evidence is still limited [@pgen.1003284-Chlebowski1]. It is thus plausible that estrogen only MHT modifies the relative risk for genetic variants in *RAD51L1* on breast cancer risk.

*NRIP1* (nuclear receptor--interacting protein 1), also called *RIP140* (receptor-interacting protein 140), is known to interact with ERα, repress ER signaling and inhibit its mitogenic effects [@pgen.1003284-Ghoussaini1]. Exposure to exogenous estrogens through MHT, which stimulate ER signalling, could therefore alter the association of *NRIP1* rs2823093 with breast cancer.

It is less clear how 2q35-rs13387042 might be modified by current combined estrogen/progestagen MHT use since the gene involved at this locus is still unknown. The SNP is located on the short arm of chromosome 2 and lies in a linkage disequilibrium (LD) block containing no known gene(s) or non-coding RNAs. The closest known genes are *TNP1* (transition protein 1), *IGFBP5* (insulin-like growth factor binding protein 5), *IGFBP2* (insulin-like growth factor binding protein 2) and *TNS1* (tensin 1/matrix-remodelling-associated protein 6) [@pgen.1003284-Stacey1]. The observed effect modification would suggest that the gene involved may be responsive to steroid hormones.

Both Campa et al. and the Million Women Study investigated potential interactions with MHT (overall use) [@pgen.1003284-Campa1], [@pgen.1003284-Travis1]. Neither study reported evidence for interaction between 2q35-rs13387042 or *RAD51L1*-rs999737 with MHT and breast cancer risk. However, neither study considered current use of MHT even though elevated risks for breast cancer have been clearly established for current use and not for past use [@pgen.1003284-Travis1], [@pgen.1003284-Beral1], [@pgen.1003284-FleschJanys1]. Yet Campa et al. found differences in OR estimates for 2q35-rs13387042 by ever use of combined estrogen/progestagen MHT in the same direction as our results for current combined estrogen/progestagen MHT use, with a per-allele OR of 0.83 (0.78--0.89) in non-users and 0.77 (0.69--0.86) in ever combined estrogen/progestagen MHT users (P-value = 0.26) (in their Supplementary Table 5). We were not able to confirm the previously suggested possible interaction of 5p12-rs10941679 or *FGFR2* variants with MHT and other factors [@pgen.1003284-Campa1]--[@pgen.1003284-Rebbeck1]. Our data suggest that age at first birth in parous women may modify the effect of 11q13-rs614367, which is located in a region containing no known genes [@pgen.1003284-Turnbull1]. This newly identified SNP has not been previously assessed for interaction with environmental risk factors.

One of the strengths of our study is the large sample size, required for assessing weak to moderate gene-environment interactions, particularly when marker SNPs instead of causal variants are used [@pgen.1003284-Hein1]. We assessed gene-environment interaction separately for ER-positive and ER-negative disease, thereby accounting for heterogeneity by ER status in risk associated with both genetic and environmental factors. However, statistical power was still limited to detect interactions in susceptibility to ER-negative disease. Although selection bias is likely to affect estimates of environmental main effects, under reasonable assumptions, it should not influence the assessment of multiplicative gene-environment interactions or estimates of SNP relative risks [@pgen.1003284-Morimoto1]. Furthermore, both non-differential and differential misclassification of exposure tend to underestimate the multiplicative interaction parameter rather than yield spurious evidence of interaction [@pgen.1003284-GarciaClosas1]. To reduce potential bias due to population stratification, we restricted our analyses to subjects of European ancestry and stratified by study in all analyses. The robustness of our findings to differences in study design was supported by sensitivity analyses considering only data from population-based studies. The interaction estimates also did not change substantially when adjusting for further covariates: the p-values were however higher due to the considerably reduced sample sizes. The absence of study heterogeneity in the estimates of gene-environment interactions provides further reassurance of the robustness of the findings.

The effect modifications identified in our study are relatively weak and should result in small differences in risk estimates of joint effects compared to those based on models assuming multiplicative effects. However, most of the SNPs investigated are only markers of the underlying causal variants and underestimate the effects of the causal variants if linkage disequilibrium is incomplete [@pgen.1003284-Zondervan1]. Thus, gene-environment interactions with the underlying causal variant could have a greater modifying effect on the relative risk [@pgen.1003284-Hein1]. These findings also underline the importance of investigating interactions separately for causally distinct subtypes of breast cancer in future assessments of gene-environment interaction.

In summary, we provide strong evidence of effect modification of *LSP1-*rs3817198 by number of births and of *CASP8*-rs1045485 by alcohol consumption. For some additional common genetic variants, the associations with breast cancer risk may vary with environmental factors. However, there is little evidence for multiplicative gene-environment interactions for most susceptibility loci and environmental risk factors. Understanding the biological implications of the observed interactions could provide further insight into the etiology of breast cancer. The potential impact of these results on risk prediction for breast cancer needs to be considered in future studies.

Methods {#s4}
=======

Study participants and risk factor data {#s4a}
---------------------------------------

We used primary data from the studies in BCAC. All studies had approval from the relevant ethics committees and all participants gave informed consent. A centralized BCAC database of information about common risk factors and tumor characteristics was constructed to facilitate studies of potential modifications of SNP associations by other risk factors. A multi-step data harmonization procedure was used to reconcile differences in individual study questionnaires. The reference age for cohort studies was calculated at time of enrollment and for case-control studies at date of diagnosis for cases and at date of interview for controls. All time-dependent variables were assessed at reference age. This analysis included only subjects of European ancestry that had genotype data for at least 3 SNPs and provided information on at least one of the established risk factors. Relevant data were available from 24 studies, including 16 population-based studies (14 case-control and 2 prospective cohort studies) and 8 non-population-based studies ([Table 1](#pgen-1003284-t001){ref-type="table"}, [Table S1](#pgen.1003284.s001){ref-type="supplementary-material"}, [Table S2](#pgen.1003284.s002){ref-type="supplementary-material"}). Subsets of data from 19 studies (with 11 population-based) were included in a previous report that assessed interactions between 12 susceptibility variants, reproductive history, BMI and breast cancer risk [@pgen.1003284-Milne1].

SNP selection and genotyping {#s4b}
----------------------------

We included 21 SNPs found to be associated with overall breast cancer risk at genome-wide statistical significance (p\<5×10^−7^) [@pgen.1003284-Broeks1], [@pgen.1003284-Ghoussaini1], [@pgen.1003284-Fletcher1] and SNPs for *TGFB1* and *CASP8* from candidate gene studies [@pgen.1003284-Cox1] ([Table S3](#pgen.1003284.s003){ref-type="supplementary-material"}). For three loci, 14q24.1/*RAD51L1*, 12p11, *CASP8*, a surrogate SNP in high linkage disequilibrium (LD) (*r^2^* = 1 in HapMap CEU) was genotyped in a subset ([Table 3](#pgen-1003284-t003){ref-type="table"} footnote) [@pgen.1003284-Figueroa1], [@pgen.1003284-Ghoussaini1], [@pgen.1003284-Thomas1].

Genotyping was performed in the framework of BCAC by Taqman and iPlex assays and underwent quality control as described previously [@pgen.1003284-Broeks1], [@pgen.1003284-Figueroa1], [@pgen.1003284-Ghoussaini1], [@pgen.1003284-Fletcher1], [@pgen.1003284-Milne2], [@pgen.1003284-Milne3]. Genotype data were excluded from analysis on a study-by-study basis according to the following BCAC quality control (QC) guidelines: 1) any sample that consistently failed for \>20% of the SNPs within a genotyping round, 2) all samples on any one plate that had a call rate \<90% for any one SNP, 3) all genotype data for any SNP where overall call rate was \<95%, 4) all genotype data for any SNP where duplicate concordance was \<98%. In addition, for any SNP where the P-value for departure from Hardy-Weinberg proportions for controls was \<0.005, clustering of the intensity plots was reviewed manually and the data excluded if clustering was judged to be poor.

Statistical methods {#s4c}
-------------------

We used logistic regression to assess the main effects of the SNP and environmental risk factors on invasive breast cancer risk. Analyses were adjusted for study as a categorical variable and reference age as a continuous variable. Odds ratios (OR) and their 95% confidence intervals (CI) were calculated for the SNP associations assuming a log-additive model and tested for association with a one degree of freedom trend test. All statistical tests were two-sided.

The assessment of associations with the environmental risk factors was based on data only from the 16 population-based studies to ensure unbiased estimates for comparison with established effect sizes. The variables considered were analyzed as continuous (age at menarche, number of births in parous women, age at first birth, usual BMI, height, duration of oral contraceptive use, duration of current use of estrogen-progestagen combined therapy, duration of current use of estrogen-only therapy, pack-years of cigarette smoking, mean lifetime daily grams of alcohol intake, recent physical activity in hours per week), or as dichotomous (ever parous, ever breastfed, ever OC use, ever smoked, current EPT use, current ET use) ([Table 2](#pgen-1003284-t002){ref-type="table"}). Analyses were performed for all women as well as separately for women aged \<54 years and ≥54 years, considering the age groups as surrogates of pre- and postmenopausal status, Differential effects by menopausal status were assessed by adding an interaction term. For all categorical variables, the lowest level of exposure (or no use) was used as the reference. For evaluating current use of MHT by type, we used never use of MHT as the reference category and additionally adjusted for former use of MHT and other MHT type, as appropriate.

To test for interactions between SNPs and environmental risk factors, we fitted for each SNP two logistic models, a model with terms for the SNP and the risk factor of interest and another model with additionally an interaction term for the product between the SNP (number of risk alleles) and the risk factor variable. We modeled the interaction based on the risk factor variable definitions employed for the main effects. All analyses were stratified by study and adjusted for age as a continuous variable. The likelihood ratio test was used to compare the difference between the two models and departure from independent multiplicative effects of the SNP and the risk factor. BMI was the only variable found to show differential effects by menopausal status, which is consistent with the literature [@pgen.1003284-vandenBrandt1]. Therefore, interaction between SNPs and BMI was assessed separately for pre- and postmenopausal women whereas all other risk factors were evaluated regardless of menopausal status. To assess study heterogeneity, we calculated odds ratios for interaction for each individual study, adjusting for age, and reported P-values for heterogeneity using a Q-test. Subjects with missing data for a particular SNP or environmental factor were excluded from the respective analysis. We also calculated stratum specific per-allele ORs for each SNP: age at menarche (≤11, 12--13, ≥14 years), number of births (1,2,3, ≥4), age at first birth (\<20, 20--24, 25--29, ≥30 years), usual BMI (\<25, 25--29, ≥30), height (\<160, 160--164, 165--169, ≥170 cm), duration of oral contraceptive use and of menopausal hormone use (0, \>0--\<5, 5--\<10, ≥10 years), mean lifetime alcohol intake (0, 0--\<10, 10--\<20, ≥20 g/day), pack-years of smoking (0, 1--\<10, 10--\<20, ≥20), and physical activity (0, \>0--\<3.5, ≥3.5--\<7, ≥7 h/week).

For SNP-environment interactions with associated P-value\<10^−3^, we also compared results after adjusting for additional covariates. We performed a total of 414 (23 SNPs x 18 risk variables) tests. To account for chance findings due to multiple comparisons, we calculated the false positive report probability (FPRP) for SNP-environment interactions with associated P-value\<10^−3^ [@pgen.1003284-Wacholder1]. The FPRP depends on the prior probability that the association between the SNP and breast cancer is modified by the environmental risk factor, the power of the present study, and the observed P-value. Since the prior probability of the assessed multiplicative interactions varies depending on subjective evaluation of existing evidence, we calculated the FPRPs for prior probabilities ranging from 0.05 to 0.0001. We considered findings with FPRP below 0.2 to be noteworthy results, as previously proposed [@pgen.1003284-Wacholder1].

In secondary analyses, we examined associations and effect modifications separately for women with ER-positive tumors and ER-negative tumors, each compared to all controls. Effect heterogeneity by ER status was tested using case-case analysis.

Data harmonization was performed using an ACCESS database and transformation of the data elements was performed using SAS (Release 9.2). All other data analyses were conducted using SAS (Release 9.2) and the R programming language [@pgen.1003284-R1].
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